Stay updated on Baricitinib in Pediatric Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Baricitinib in Pediatric Atopic Dermatitis Clinical Trial page.

Latest updates to the Baricitinib in Pediatric Atopic Dermatitis Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedPublications section description updated to state that publications are automatically filled from PubMed and may not be about the study, and the revision label changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check28 days agoChange Detected- The lapse in government funding notice about NIH operations was removed from the page. - This notice was administrative and did not alter trial content.SummaryDifference0.2%

- Check42 days agoChange DetectedThe changes appear to be minor UI adjustments and wording edits; no core trial details, eligibility criteria, outcomes, or enrollment numbers were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check71 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating a status update and potential operational limitations. - Updated version from v3.1.0 to v3.2.0.SummaryDifference1%

- Check78 days agoChange DetectedAppended version label (v3.1.0) and removal of multiple drug-safety related sections, indicating content consolidation and reorganization rather than new substantive content.SummaryDifference0.1%

- Check92 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed, a minor navigation change.SummaryDifference0.1%

Stay in the know with updates to Baricitinib in Pediatric Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Baricitinib in Pediatric Atopic Dermatitis Clinical Trial page.